A serological investigation in Southern Italy: was SARS-CoV-2 circulating in late 2019?

References

• World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. [accessed 2021 Nov 29]. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020.
   Google Scholar
• World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. 2020. [accessed 2021 Nov 29]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-covid-2019-and-the-virus-that-causes-it
   Google Scholar
• den Hartog G, Schepp RM, Kuijer M, GeurtsvanKessel C, van Beek J, Rots N, Koopmans MPG, van der Klis FRM, van Binnendijk RS. SARS-CoV-2-Specific antibody detection for seroepidemiology: a multiplex analysis approach accounting for accurate seroprevalence. J Infect Dis. 2020;222(9):1452–9. doi:10.1093/infdis/jiaa479. PMID: 32766833.
   PubMed Web of Science ®Google Scholar
• eCDC. Immune responses and immunity to SARS-CoV-2. 2021 29/11/2021]. [accessed 2021 Nov 29]. https://www.ecdc.europa.eu/en/covid-19/latest-evidence/immune-responses.
   Google Scholar
• Zervou FN, Louie P, Stachel A, Zacharioudakis IM, Ortiz-Mendez Y, Thomas K, Aguero-Rosenfeld ME. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection. J Med Virol. 2021;93(9):5409–15. doi:10.1002/jmv.27058. PMID: 3393229.
   PubMed Web of Science ®Google Scholar
• Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, Quentric P, Fadlallah J, Devilliers H, Ghillani P et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021 PMID: 33288662;13(577):eabd2223. doi:10.1126/scitranslmed.abd2223.
   PubMed Web of Science ®Google Scholar
• Quinti I, Mortari EP, Fernandez Salinas A, Milito C, Carsetti R. IgA antibodies and IgA deficiency in SARS-CoV-2 infection. Front Cell Infect Microbiol. 2021;11:655896. doi:10.3389/fcimb.2021.655896. PMID: 33889552.
   PubMed Web of Science ®Google Scholar
• Blackberg A, Fernstrom N, Sarbrant E, Rasmussen M, Sunnerhagen T, Zivkovic AR. Antibody kinetics and clinical course of COVID-19 a prospective observational study. PLoS One. 2021;16(3):e0248918. doi:10.1371/journal.pone.0248918. PMID: 33750984.
   PubMed Web of Science ®Google Scholar
• Morawska L, Cao J. Airborne transmission of SARS-CoV-2: the world should face the reality. Environ Int. 2020;139:105730. doi:10.1016/j.envint.2020.105730. PMID: 32294574.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. doi:10.1056/NEJMoa2001017. PMID: 31978945.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5. PMID: 3198626.
   PubMed Web of Science ®Google Scholar
• Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, Ng OT, Marimuthu K, Ang LW, Mak TM et al. Singapore novel coronavirus outbreak research, epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. Jama. 2020;323(15):1488–94. doi:10.1001/jama.2020.3204. PMID: 32125362.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Coronavirus disease 2019 (COVID-19) Situation Report – 46. [accessed 2021 Nov 13]. https://apps.who.int/iris/handle/10665/331443
   Google Scholar
• World Health Organization. Transmission of COVID-19 by asymptomatic cases. 2021 29 Nov]. [accessed 2021 Nov 13]. http://www.emro.who.int/health-topics/corona-virus/transmission-of-covid-19-by-asymptomatic-cases.html.
   Google Scholar
• Nogrady B. What the data say about asymptomatic Covid Infections. Nature. 2020 PMID: 33214725;587(7835):534–35. doi:10.1038/d41586-020-03141-3.
   PubMed Web of Science ®Google Scholar
• Pollock AM. Asymptomatic transmission of covid-19. thebmj. 2020;371(m4851):1–2. doi:10.1136/bmj.m4851.
   Google Scholar
• Nikolai LA, Meyer CG, Kremsner PG, Velavan TP. Asymptomatic SARS Coronavirus 2 infection: invisible yet invincible. Int J Infect Dis. 2020;100:112–16. PMID: 32891737. doi:10.1016/j.ijid.2020.08.07.
   PubMed Web of Science ®Google Scholar
• eCDC. Threat assessment brief: outbreak of novel coronavirus disease 2019 (COVID-19): situation in Italy. 2020.
   Google Scholar
• Istituto Superiore di Sanità, EPIDEMIA COVID-19. Aggiornamento nazionale 2 Aprile 2020. 2020.
   Google Scholar
• Vicentini C, Bordino V, Gardois P, Zotti CM. Early assessment of the impact of mitigation measures on the COVID-19 outbreak in Italy. Public Health. 2020;185:99–101. PMID: 32593056. doi:10.1016/j.puhe.2020.06.028.
   PubMed Web of Science ®Google Scholar
• WHO. Italy: WHO Coronavirus disease (COVID-19) dashboard 2021. [ accessed 2021 Nov 29]. https://covid19.who.int/region/euro/country/it.
   Google Scholar
• Statistica. Distribution of coronavirus cases in Italy as of June 23, 2021, by age group. [2021 Nov 19]. https://www.statista.com/statistics/1103023/coronavirus-cases-distribution-by-age-group-italy/
   Google Scholar
• Statistica. Most common comorbidities observed in coronavirus (COVID-19) deceased patients in Italy as of July 22, 2020. [accessed 2021 Nov 19] https://www.statista.com/statistics/1110949/common-comorbidities-in-covid-19-deceased-patients-in-italy/.
   Google Scholar
• Statistica. Coronavirus (COVID-19) death rate in Italy as of April 21, 2021, by age group. [ accessed 2021 Nov 13] https://www.statista.com/statistics/1106372/coronavirus-death-rate-by-age-group-italy/.
   Google Scholar
• Ministero della Salute. Covid-19 - Situazione in Italia. 2020 April 12. [ accessed 2021 Nov 29]. http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?area=nuovoCoronavirus&id=5351&lingua=italiano&menu=vuoto
   Google Scholar
• Mazzini L, Martinuzzi D, Hyseni I, Benincasa L, Molestti E, Casa E, Lapini G, Piu P, Trombetta CM, Marchi S et al. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. J Immunol Methods. 2021;489:112937. doi:10.1016/j.jim.2020.112937. PMID: 33253698.
   PubMed Web of Science ®Google Scholar
• Milani GP, Dioni L, Favero C, Cantone L, Macchi C, Delbue S, Bonzini M, Montomoli E, Bollati V, Consortium U. Serological follow-up of SARS-CoV-2 asymptomatic subjects. Sci Rep. 2020;10(1):20048. doi:10.1038/s41598-020-77125-8. PMID: 33208819.
   PubMed Web of Science ®Google Scholar
• Manenti A, Maggetti M, Casa E, Martinuzzi D, Torelli A, Trombetta CM, Marchi S, Montomoli E. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples. J Med Virol. 2020;92(10):2096–104. doi:10.1002/jmv.25986. PMID: 32383254.
   PubMed Web of Science ®Google Scholar
• Marchi S, Viviani S, Remarque EJ, Ruello A, Bombardieri E, Bollati V, Milani GP, Manenti A, Lapini G, Rebuffat A et al. Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. PLoS One. 2021;16(7):e0253977. doi:10.1371/journal.pone.0253977. PMID: 34214116.
   PubMed Web of Science ®Google Scholar
• Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K, Arunkumar GA, Jurczyszak D, Polanco J et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26(7):1033–36. doi:10.1038/s41591-020-0913-5. PMID: 32398876.
   PubMed Web of Science ®Google Scholar
• Lv H, Wu NC, Tsang OT, Yuan M, Perera R, Leung WS, So RTY, Chan JMC, Yip GK, Chik TSH et al. Cross-Reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep. 2020;31(9):107725. doi:10.1016/j.celrep.2020.107725.
   PubMed Web of Science ®Google Scholar
• Nguyen-Contant P, Embong AK, Kanagaiah P, Chaves FA, Yang H, Branche AR, Topham DJ, Sangster MY, Ellebedy A, Schultz-Cherry MY. S protein-reactive IgG and memory B cell production after Human SARS-CoV-2 infection includes broad reactivity to the S2 subunit. mBio. 2020;11(5): e01991–20. doi:10.1128/mBio.01991-20. PMID: 32978311.
   PubMed Web of Science ®Google Scholar
• Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon M, Meade P, Mendu DR, Muellers K et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227–30. doi:10.1126/science.abd7728. PMID: 33115920.
   PubMed Web of Science ®Google Scholar
• Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, Hemmings O, O’-Byrne A, Kouphou N, Galao RP et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598–607. doi:10.1038/s41564-020-00813-8. PMID: 33106674.
   PubMed Web of Science ®Google Scholar
• Apolone G, Montomoli E, Manenti A, Boeri M, Sabia F, Hyseni I, Mazzini L, Martinuzzi D, Cantone L, Milanese G et al. Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy. Tumori. 2020;107(5):446–51. doi:10.1177/0300891620974755.
   PubMed Web of Science ®Google Scholar
• Krammer F, Simon V. Serology assays to manage COVID-19. Science. 2020;368(6495):1060–61. doi:10.1126/science.abc1227. PMID: 32414781.
   PubMed Web of Science ®Google Scholar
• Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl C, Wrobel AG, Benton DJ et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370(6522):1339–43. doi:10.1126/science.abe1107. PMID: 33159009.
   PubMed Web of Science ®Google Scholar
• Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, Teo C, Arunkumar GA, McMahon M, Capuano C et al. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. Nature. 2020;590(7844):146–50. doi:10.1038/s41586-020-2912-6.
   PubMedGoogle Scholar
• CDC. Interim guidelines for COVID-19 antibody testing. [ accessed 2021 Nov 29]. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html.
   Google Scholar
• Kumar S, Tao Q, Weaver S, Sanderford M, Caraballo-Ortiz MA, Sharma S, Pond SLK, Miura S. An evolutionary portrait of the progenitor SARS-CoV-2 and its dominant offshoots in COVID-19 pandemic. Mol Biol Evol. 2021;38(8):3046–59. doi:10.1093/molbev/msab118. PMID: 33942847.
   PubMed Web of Science ®Google Scholar
• Kolbl O, Analysis of the information transmission chain in academic research reveals reluctance to accept early circulation of SARS-CoV-2. 2021. https://www.researchgate.net/publication/353982851_Analysis_of_the_information_transmission_chain_in_academic_research_reveals_reluctance_to_accept_early_circulation_of_SARS-_CoV-2
   Google Scholar
• World Health Organization. COVID-19 natural immunity. https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-Natural_immunity-2021.1 2021.
   Google Scholar
• Percivalle E, Cambie G, Cassaniti I, Nepita EV, Maserati R, Ferrari A, Di Martino R, Isernia P, Mojoli F, Bruno R et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 2020 April 6. Euro Surveill. 2020;2524:2001031. doi:10.2807/1560-7917.ES.2020.25.24.2001031. PMID: 32583766.
   PubMedGoogle Scholar
• Takeshita M, Nishina N, Moriyama S, Takahashi Y, Uwamino Y, Nagata M, Aoki W, Masaki K, Ishii M, Saya H et al.; . P. Keio Donner ; Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan. Virology. 2021;555:35–43. doi:10.1016/j.virol.2020.12.020. PMID: 33450669.
   PubMed Web of Science ®Google Scholar
• Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200–04. doi:10.1038/s41591-020-0965-6. PMID: 32555424.
   PubMed Web of Science ®Google Scholar
• Ding S, Laumaea A, Benlarbi M, Beaudoin-Bussieres G, Gasser R, Medjahed H, Pancera M, Stamatatos L, McGuire AT, Bazin R et al. Antibody binding to SARS-CoV-2 S glycoprotein correlates with but does not predict neutralization. Viruses. 2020 PMID: 33114742;12(11):1214. doi:10.3390/v12111214.
   PubMed Web of Science ®Google Scholar
• La Rosa G, Mancini P, Bonanno Ferraro G, Veneri C, Iaconelli M, Bonadonna L, Lucentini L, Suffredini E. SARS-CoV-2 has been circulating in northern Italy since December 2019: evidence from environmental monitoring. Sci Total Environ. 2021;750:141711. PMID: 32835962. doi:10.1016/j.scitotenv.2020.141711.
   PubMed Web of Science ®Google Scholar
• La Rosa G, Iaconelli M, Mancini P, Bonanno Ferraro G, Veneri C, Bonadonna L, Lucentini L, Suffredini E. First detection of SARS-CoV-2 in untreated wastewaters in Italy. Sci Total Environ. 2020;736:139652. doi:10.1016/j.scitotenv.2020.139652. PMID: 32464333.
   PubMed Web of Science ®Google Scholar
• Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M, Lombardi A, Berzuini A, Caprioli F, Santoro L, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. Blood Transfus. 2021;19(3):181–89. doi:10.2450/2021.0324-20.
   PubMed Web of Science ®Google Scholar
• Gragnani L, Monti M, Santini SA, Marri S, Madia F, Lorini S, Petraccia L, Stasi C, Basile U, Luti V et al. SARS-CoV-2 was already circulating in Italy, in early December 2019. Eur Rev Med Pharmacol Sci. 2021;25(8):3342–49. doi:10.26355/eurrev_202104_25746. PMID: 33928622.
   PubMed Web of Science ®Google Scholar
• Gianotti R, Barberis M, Fellegara G, Galvan-Casas C, Gianotti E. COVID-19-Related dermatosis in November 2019: could this case be Italy’s patient zero? Br J Dermatol. 2021;184(5):970–71. doi:10.1111/bjd.19804. PMID: 33410129.
   PubMed Web of Science ®Google Scholar
• Amendola A, Bianchi S, Gori M, Colzani D, Canuti M, Borghi E, Raviglione MC, Zuccotti GV, Tanzi E. Evidence of SARS-CoV-2 RNA in an Oropharyngeal swab specimen, Milan, Italy, Early December 2019. Emerg Infect Dis. 2021 PMID: 33292923;27(2):648–50. doi:10.3201/eid2702.204632.
   PubMed Web of Science ®Google Scholar
• Amendola A. Molecular evidence for SARS-CoV-2 in samples collected from patients with Morbilliform eruptions since Late Summer 2019 in Lombardy, Northern Italy. 2021. https://www.researchgate.net/publication/353751558_Molecular_evidence_for_SARS-CoV-2_in_samples_collected_from_patients_with_morbilliform_eruptions_since_late_summer_2019_in_Lombardy_Northern_Italy
   Google Scholar
• Zehender G, Lai A, Bergna A, Meroni L, Riva A, Balotta C, Tarkowski M, Gabrieli A, Bernacchia D, Rusconi S et al. Genomic characterization and phylogenetic analysis of SARS-COV-2 in Italy. J Med Virol. 2020 PMID: 32222993;92(9):1637–40. doi:10.1002/jmv.25794.
   PubMed Web of Science ®Google Scholar
• ANSA. Alzano, le 110 polmoniti ‘atipiche’ al vaglio degli inquirenti. 2020. https://www.ansa.it/lombardia/notizie/2020/06/30/alzanoin-inverno-110-polmoniti-strane_4edeed5d-23b8-46a8-ab78-266f839fbb5a.html.
   Google Scholar
• Lombardi F, Belmonti S, Ricci R, Borghetti A, Fabbiani M, Ciccullo A, Cauda R, Di Giambenedetto S. No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy. Clin Microbiol Infect. 2020 PMID: 33278571;27(5):802–04. doi:10.1016/j.cmi.2020.11.026.
   PubMed Web of Science ®Google Scholar
• Capalbo C, Bertamino E, Zerbetto A, Santino I, Petrucca A, Mancini R, Bonfini R, Alfonsi V, Ferracuti S, Marchetti P et al. No evidence of SARS-CoV-2 circulation in Rome (Italy) during the pre-pandemic period: results of a retrospective surveillance. Int J Environ Res Public Health. 2020;17(22):8461. doi:10.3390/ijerph17228461. PMID: 33207548.
   PubMed Web of Science ®Google Scholar
• Rizzo C, Loconsole D, Pandolfi E, Ciofi Degli Atti ML, van Summeren J, Paget J, Russo L, Campagna I, Croci I, Gesualdo F et al. Sars-Cov2 not detected in a pediatric population with acute respiratory infection in primary care in Central and Southern Italy from November 2019 to Early March 2020. Front Pediatr. 2021;9:620598. PMID: 34046372. doi:10.3389/fped.2021.620598.
   PubMed Web of Science ®Google Scholar
• Deslandes A, Berti V, Tandjaoui-Lambotte Y, Alloui C, Carbonnelle E, Zahar JR, Brichler S, Cohen Y. SARS-CoV-2 was already spreading in France in late December 2019. Int J Antimicrob Agents. 2020;55(6):106006. doi:10.1016/j.ijantimicag.2020.106006.
   PubMed Web of Science ®Google Scholar
• Carrat F, Figoni J, Henny J, Desenclos JC, Kab S, de Lamballerie X, Zins M. Evidence of early circulation of SARS-CoV-2 in France: findings from the population-based “CONSTANCES” cohort. Eur J Epidemiol. 2021 PMID: 33548003;36(2):219–22. doi:10.1007/s10654-020-00716-2.
   PubMed Web of Science ®Google Scholar
• Nsoesie EO, Rader B, Barnoon YL, Goodwin K. Analysis of hospital traffic and search engine data in Wuhan China indicates early disease activity in the Fall of 2019. HARVARD LIBRARY Office for Scholarly Communication. 2020;1–9. https://dash.harvard.edu/handle/1/42669767
   Google Scholar
• Basavaraju SV, Patton ME, Grimm K, Rasheed MAU, Lester S, Mills L, Stumpf M, Freeman B, Tamin A, Harcourt J et al. Serologic Testing of US blood donations to identify severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2)-reactive antibodies: December 2019-January 2020. Clin Infect Dis. 2021;72(12):e1004–e1009. doi:10.1093/cid/ciaa1785.
   PubMed Web of Science ®Google Scholar
• Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, Silacci-Fregni C, Pinto D, Rosen LE, Bowen JE et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 Spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024–42.e21. doi:10.1016/j.cell.2020.09.037. PMID: 32991844.
   PubMed Web of Science ®Google Scholar